ArticleBMC infectious diseases2025
Factors influencing QT interval prolongation during rifampicin-resistant tuberculosis treatment: a multicenter real-world study from China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a LASSO-derived nomogram for predicting unfavorable treatment outcomes in drug-resistant pulmonary tuberculosis.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundWe sought to assess the factors influencing QTc interval prolongation in patients with multidrug- or rifampicin-resistant tuberculosis.
methodsWe conducted a retrospective cohort study of admissions with multidrug-resistant or rifampicin-resistant tuberculosis as the primary diagnosis from nine regions in China between May 2018 and June 2020. Guided by directed acyclic graphs, we developed two multivariable logistic regression models to account for identified confounders and examine their impact on outcomes across different aspects. Results were represented as odds ratios with 95% confidence intervals. Statistical analysis was performed using RStudio.
resultsAmong the 1,421 patients included in the study, 1,293 (91.0%) had normal QTc intervals, while 128 (9.0%) exhibited prolonged QTc intervals. In treatment regimens-based adjusted models, treatment regimens containing bedaquiline and/or linezolid, baseline QTc prolongation (≥ 450 ms), hypertension, and pre-treatment anemia were significantly associated with an increased risk of QTc interval prolongation. Comorbidity-based adjusted models showed that baseline QTc interval prolongation, hypertension, pre-treatment anemia, and adverse events during treatment including gastrointestinal reactions, liver and kidney injury, and electrolyte imbalances were strongly correlated with QTc interval prolongation.
conclusionsOur study demonstrates that baseline QTc prolongation, hypertension and choice of treatment regimens significantly increase the risk of QTc interval prolongation in patients with multidrug- and rifampicin-resistant tuberculosis. Additionally, adverse events during treatment further elevate this risk and require careful monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.